Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction

Journal of Clinical Pharmacology

Volumn 53, Issue 9, 2013, Pages 967-973

  Tsuji, Yasuhiro ^a   Yukawa, Eiji ^b   Hiraki, Yoichi ^c   Matsumoto, Kana ^d   Mizoguchi, Akiko ^e   Morita, Kunihiko ^d   Kamimura, Hidetoshi ^f   Karube, Yoshiharu ^f   To, Hideto ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^d DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^e SASEBO CHUO HOSPITAL   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

Author keywords

Linezolid; Methicillin resistant staphylococcus aureus; Nonlinear mixed effects modeling; Population pharmacokinetics; Renal dysfunction

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; LINEZOLID;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DYSFUNCTION; MALE;

LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NONLINEAR MIXED EFFECTS MODELING; POPULATION PHARMACOKINETICS; RENAL DYSFUNCTION;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MODELS, BIOLOGICAL; OXAZOLIDINONES; RENAL INSUFFICIENCY; STAPHYLOCOCCAL INFECTIONS;

EID: 84885074533     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.133     Document Type: Article

References (22)

1. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U- 100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996;40:839-845. (Pubitemid 26117523)
2. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs. 1999;8:1195- 1202. (Pubitemid 29410576)
3. Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1999;43:2059-2062. (Pubitemid 29395210)
4. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos. 2001;29:136-145.
5. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57:793- 797. (Pubitemid 34143337)
6. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003;47:2775-2780. (Pubitemid 37040247)
7. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695-698. (Pubitemid 34165334)
8. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46:2723-2726. (Pubitemid 34793498)
9. Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolidassociated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28:345-351.
10. Matsumoto K, Takeda Y, Takeshita A, et al. Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents. 2009;33:98-99.
11. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-2100. (Pubitemid 41623371)
12. Majcher-Peszynska J, Haase G, Sass M, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol. 2008;64:1093-1100.
13. Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49:1071-1078.
14. Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011;55:1867-1873.
15. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982-992.
16. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47:548-553. (Pubitemid 36158080)
17. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254. (Pubitemid 46768608)
18. Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification -foreword. Am J Kidney Dis. 2002;39(2 suppl 1):S1-226.
19. Tsuji Y, Hiraki Y, Matsumoto K, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17:70-75.
20. Hiraki Y, Tsuji Y, Matsumoto K, et al. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci. 2011;342:456-460.
21. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 2006;50:2455- 2463. (Pubitemid 43993186)
22. Beal S L, Sheiner L.B. NONMEM User's Guides. San Francisco, CA: University of California; 1999.